N30 Pharma Initiates Phase 1 Trials Of Novel Reductase Inhibitor
N30 Pharmaceuticals, LLC announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings…
Human Anthrax Infections Reach 327 Cases In Bangladesh
According to Bangladesh’s Fisheries and Livestock Ministry, 327 people have become infected with anthrax in five districts in the north of the country since August 18th. Some experts believe two other districts may also be affected. So far, approximately 150 cattle have become infected and died. Local health officials say this is the largest anthrax outbreak in the history of Bangladesh…
2nd Annual Cancer Targets And Therapeutics Conference, Oct 20-22, San Francisco, CA
Dr. Patrick Baeuerle, Vice President of Micromet, to present as a featured speaker at GTCbio’s 2nd Annual Cancer Targets and Therapeutics Conference, part of the 6th Modern Drug Discovery and Development Summit on Oct. 20-22, 2010 in San Francisco, CA. Dr. Baeuerle will give a presentation on “BiTE Antibody-Engaged T-Cells for Cancer Therapy…
Molecules Involved In Touch And Other Mechanically Activated Systems Identified
Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction. The study was published in Science Express, the advanced, online edition of the journal Science…
MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment In Open-Label Trial And Completion Of Treatment In QT Trial For LEVADEXtm
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX…
California Whooping Cough Rate 7 Times Higher Than Last Year
Latest reports, up to the end of August place the number of reported whooping cough (pertussis) cases in the state of California at 3,311, a seven-fold increase over the same period in 2009 when the figure reached 501 cases, says the California Department of Public Health. Health authorities estimate a state rate of 9.2 cases per 100,000 inhabitants…
Review: Helping Kids Cope With Chemo
Although nausea and vomiting are common in children undergoing chemotherapy, few quality studies identify absolutely the best way to prevent and treat this problem in kids, said Robert Phillips, M.D., lead author of a new Cochrane review. Phillips, a pediatric oncologist at St. James’s Hospital in Leeds, England, said the main finding is the paucity of data that he and his colleagues uncovered…
How Bone-Marrow Stem Cells Hold Their ‘Breath’ In Low-Oxygen Environments
UT Southwestern Medical Center researchers have identified unique metabolic properties that allow a specific type of stem cell in the body to survive and replicate in low-oxygen environments…
Enobia Provides Update On Progress With ENB-0040, A Bone-Targeted Enzyme Replacement Therapy For Hypophosphatasia
Enobia Pharma provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages…
74,700 Bags Of Possibly Salmonella Tainted Beef Treats For Dogs Recalled , Says FDA
The FDA (Food and Drug Administration) announced that The Hartz Mountain Corporation has voluntarily recalled 74,800 8-ounce bags of Hartz Naturals Real Beef Treats for Dogs which may be tained with Salmonella. Infection with salmonella, known as salmonellosis, can affect pets, such as dogs and cats, as well as humans - it is caused by Salmonella bacteria…
